Selection of an Antidepressant Based on the Genotypes of Cytochrome P450 Enzymes Genes in a Patient with Major Depressive Disorder.
- Author:
Seunghyong RYU
1
;
Soo Youn LEE
;
Jong Won KIM
;
Kyung Sue HONG
Author Information
1. Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. kshong@smc.samsung.co.kr
- Publication Type:Case Report
- Keywords:
Antidepressant;
Cytochrome P450 CYP2D6;
Adverse effects;
Pharmacogenetics
- MeSH:
Adult;
Cytochrome P-450 CYP2D6;
Cytochrome P-450 Enzyme System*;
Cytochromes*;
Depression;
Depressive Disorder, Major*;
Female;
Genotype*;
Humans;
Imipramine;
Paroxetine;
Pharmacogenetics
- From:Korean Journal of Psychopharmacology
2005;16(4):324-328
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
We present a case of 34-year-old female patient with major depressive disorder who had decreased metabolic activity of CYP2D6. Low dosage regimen of mirtazapine & paroxetine led to unexpectedly severe adverse effects and noncompliance in this case with genotype CYP2D6 *1/*5. Antidepressant change to imipramine with consideration of the genotyping resulted with tolerable adverse effects and remission of depression. This case suggests the clinical usefulness of pharmacogenetic testing in individualized antidepressant treatments.
